Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04387656 · ClinicalTrials.gov registry record

NCI COVID-19 in Cancer Patients, NCCAPS Study

A clinical trial of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Active
Registry status
1,877
Enrollment target
20
Study locations

NCT04387656: Active study of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).

NCT04387656 is a study of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,877 participants, above the 1,130-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04387656, a study of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
1,877 participants
Enrollment target
20
Study locations

Study Summary

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Primary Outcome

Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit \[ICU\] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.

Conditions Studied

Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Hematopoietic and Lymphatic System Neoplasm COVID-19 Infection

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • OTHER Data Collection
  • OTHER Questionnaire Administration

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Arizona

  • Kingman Regional Medical Center - Kingman
  • Banner Children's at Desert - Mesa
  • Cancer Center at Saint Joseph's - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • Veterans Administration Medical Center - Birmingham - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro

Trial Details

FieldValue
Enrollment Target 1,877 participants
Start Date 2020-06-05
Est. Completion 2026-10-03
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT04387656 still lists

NCT04387656 is an observational study that tracks outcomes without assigning an intervention. Its 1,877 participants enrollment target places it among the larger protocols in the corpus, above the 1,130-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (66% higher).

The record links to 4 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT04387656 names 20 study sites across 4 states, led by Alaska, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04387656 about?

NCT04387656 is a clinical study titled "NCI COVID-19 in Cancer Patients, NCCAPS Study". This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help r...

What is the current status of trial NCT04387656?

This trial is currently active not recruiting. The enrollment target is 1,877 participants. The study started on 2020-06-05. Estimated completion is 2026-10-03.

What conditions does trial NCT04387656 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, COVID-19 Infection.

What interventions are being tested in trial NCT04387656?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Data Collection (OTHER), Questionnaire Administration (OTHER).

Who is sponsoring clinical trial NCT04387656?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04387656 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04387656's enrollment target sits among peer trials

1,877 15th of 176 higher than 162 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05675410 · 1,875 participants · Phase 3

    A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  • NCT06891898 · 1,875 participants

    The iLet Experience Study

  • NCT07356089 · 1,875 participants

    Twiist Postmarket Surveillance Study for Type 1 Diabetes

  • NCT06438640 · 1,881 participants · NA

    Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04387656, the US trial registry maintained by the National Library of Medicine. NCT04387656 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.